ES2109228T3 - Anticuerpos monoclonales mejorados contra el receptor de las celulas t alfa/beta humano, su produccion y uso. - Google Patents

Anticuerpos monoclonales mejorados contra el receptor de las celulas t alfa/beta humano, su produccion y uso.

Info

Publication number
ES2109228T3
ES2109228T3 ES90306178T ES90306178T ES2109228T3 ES 2109228 T3 ES2109228 T3 ES 2109228T3 ES 90306178 T ES90306178 T ES 90306178T ES 90306178 T ES90306178 T ES 90306178T ES 2109228 T3 ES2109228 T3 ES 2109228T3
Authority
ES
Spain
Prior art keywords
monoclonal antibodies
antibodies against
alpha
human
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90306178T
Other languages
English (en)
Inventor
Roland Kurrle
Clyde W Shearman
Gordon P Moore
Fritz Seiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2109228T3 publication Critical patent/ES2109228T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SON DESCRITOS ANTICUERPOS MONOCLONALES CONTRA EL RECEPTOR DE CELULA-T ALFA/BETA HUMANO JUNTO CON LA PERTINENTE INFORMACION DE SECUENCIA DE LAS REGIONES VARIABLES Y CONSTANTES Y VERSIONES CIVILIZADAS Y HUMANIZADAS DE TALES ANTICUERPOS.
ES90306178T 1989-06-07 1990-06-07 Anticuerpos monoclonales mejorados contra el receptor de las celulas t alfa/beta humano, su produccion y uso. Expired - Lifetime ES2109228T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36254989A 1989-06-07 1989-06-07
US52997990A 1990-05-25 1990-05-25

Publications (1)

Publication Number Publication Date
ES2109228T3 true ES2109228T3 (es) 1998-01-16

Family

ID=27001722

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90306178T Expired - Lifetime ES2109228T3 (es) 1989-06-07 1990-06-07 Anticuerpos monoclonales mejorados contra el receptor de las celulas t alfa/beta humano, su produccion y uso.

Country Status (8)

Country Link
EP (1) EP0403156B1 (es)
JP (1) JPH03219896A (es)
AT (1) ATE157990T1 (es)
CA (1) CA2018248A1 (es)
DE (1) DE69031410T2 (es)
DK (1) DK0403156T3 (es)
ES (1) ES2109228T3 (es)
GR (1) GR3025644T3 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
FR2672901B1 (fr) * 1991-02-15 1994-09-30 Immunotech Sa Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
DE4109884A1 (de) * 1991-03-26 1992-10-01 Claas Ohg Steuerung einer verdraengermaschine eines hydrostatisch-mechanischen lastschaltgetriebes
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
CA2205138A1 (en) * 1994-11-16 1996-05-23 Baxter International Inc. Human antibodies to t-cell receptor peptides and methods for their preparation
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2735193A1 (en) * 2008-08-26 2010-03-11 Macrogenics, Inc. T-cell receptor antibodies and methods of use thereof
UY34317A (es) * 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
EP2773670A4 (en) * 2011-11-03 2015-09-02 Tolera Therapeutics Inc ANTIBODIES AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
SG11201506088RA (en) 2013-03-11 2015-09-29 Genzyme Corp Hyperglycosylated binding polypeptides
WO2015066379A2 (en) * 2013-10-30 2015-05-07 Genzyme Corporation Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
RS64072B1 (sr) 2014-03-19 2023-04-28 Genzyme Corp Mesto-specifični glikoinženjering ciljnih delova
KR20220025917A (ko) 2014-05-29 2022-03-03 마크로제닉스, 인크. 삼중-특이적 결합 분자 및 그것의 사용 방법
WO2016057769A2 (en) 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
EP3220928B1 (en) * 2014-11-20 2022-10-05 UMC Utrecht Holding B.V. A method of obtaining a preparation enrichmed in engineered t cells with exogenous immune receptors
WO2016126213A1 (en) * 2015-02-06 2016-08-11 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
WO2017106061A1 (en) 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
US20170233472A1 (en) 2016-02-17 2017-08-17 Macrogenics, Inc. ROR1-Binding Molecules, and Methods of Use Thereof
BR112018071105A2 (pt) 2016-04-15 2019-02-26 Macrogenics, Inc. conjugado de droga e anticorpo, molécula de ligação, composição farmacêutica e uso
MX2018014950A (es) 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
WO2017212072A1 (en) 2016-06-10 2017-12-14 Umc Utrecht Holding B.V. Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
SG10201912387PA (en) 2016-11-22 2020-02-27 Nat Univ Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
HRP20211744T1 (hr) 2017-07-14 2022-02-04 Immatics Biotechnologies Gmbh Poboljšana molekula polipeptida dvostruke specifičnosti
SG11202000402PA (en) 2017-08-10 2020-02-27 Nat Univ Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
GB201817172D0 (en) 2018-10-22 2018-12-05 Autolus Ltd Antibody
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
WO2020201527A1 (en) 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
CN114729305A (zh) * 2019-10-17 2022-07-08 苏州丹罗医药有限公司 用于免疫治疗的嵌合抗原受体、制备方法及其应用
US20230054266A1 (en) * 2019-12-30 2023-02-23 Edigene Biotechnology Inc. Method for purifying ucart cell and use thereof
CN113088495A (zh) * 2020-01-09 2021-07-09 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
WO2023227018A1 (zh) * 2022-05-25 2023-11-30 羿尊生物医药（浙江）有限公司 靶向细胞膜受体蛋白的融合蛋白及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product

Also Published As

Publication number Publication date
ATE157990T1 (de) 1997-09-15
JPH03219896A (ja) 1991-09-27
EP0403156B1 (en) 1997-09-10
DE69031410T2 (de) 1999-01-21
CA2018248A1 (en) 1990-12-07
DE69031410D1 (de) 1997-10-16
GR3025644T3 (en) 1998-03-31
EP0403156A1 (en) 1990-12-19
DK0403156T3 (da) 1998-04-27

Similar Documents

Publication Publication Date Title
ES2109228T3 (es) Anticuerpos monoclonales mejorados contra el receptor de las celulas t alfa/beta humano, su produccion y uso.
DE3768589D1 (de) Zusammengestelltes leichtgewichtmaterial.
DE240975T1 (de) Menschliches gamma-interferon-spezifisches rezeptorprotein, antikoerper gegen dieses protein, verfahren zur herstellung dieses proteins und dieses antikoerpers und dieses protein und diesen antikoerper enthaltende zusammensetzungen.
DE69019382D1 (de) Weiches Material für Okularlinsen.
DK101890A (da) Monoklonale antistoffer mod human interleukin-4 og hybridomaer, der producerer saadanne
DE3852054D1 (de) Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung.
DK0395853T3 (da) Rekombinant proteinreceptor
BE850505A (fr) Materiaux-supports de fermentation biologique
DE3788148D1 (de) Monoklonale Antikörper und deren Verwendung.
DE3880642T2 (de) Zusammensetzung , mit aktiven Strahlen härtbar, und Medium für die optische Registrierung mit dieser gehärteten Zusammensetzung.
DK0749481T3 (da) Humaniserede monoklonale antistoffer mod human interleukin-4
DE3682491D1 (de) Immobilisierter c-peptid-antikoerper, seine herstellung und verwendung.
DE3585049D1 (de) Monoklonale antikoerper.
DE3587714T2 (de) Menschliches alpha 2-Plasmin spezifischer monoklonaler Antikörper.
DE3583296D1 (de) Oncofetal spezifische monoklonale antikoerper, deren herstellung und verwendung.
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
ATE109834T1 (de) Monoklonaler antikörper spezifisch gegen humane pankreas-phospholipase-a2.
DE58908815D1 (de) Monoklonaler Antikörper gegen Pseudomonas aeruginosa, seine Herstellung und Verwendung.
NO874107L (no) Nye monoklonale antistoffer mot ifn-waa, fremgangsmaate til fremstilling derav og anvendelse for rensing samt paavisning av ifn-omega.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
NO974852L (no) Humant <beta>2-integrin-<alfa>-subenhet
DK31589D0 (da) Assay for begyndende diabetes, monoklonale antistoffer til anvendelse herved og saet til anvendelse hertil.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 403156

Country of ref document: ES